Companies: 10,795·Total market cap: $144.5T
Revance Therapeutics, Inc.

Revance Therapeutics, Inc.

RVNCNASDAQHealthcare
$3.65
+$0.00(+0.00%)
Market Cap$381023500
P/E Ratio—
52W High$7.56
52W Low$2.3
SEC Filings

Revance Therapeutics, Inc. (RVNC) SEC Filings & 10-K Annual Reports

SEC EDGAR regulatory submissions (10-K, 10-Q, 8-K), latest forms, and full filing history — quick links to financials and earnings below.

SEC EDGAR · data.sec.gov · CIK 0001479290 · RVNC · NASDAQ · as of Jun 10, 2026

Filing snapshot

947
Total Filings
SCHEDULE 13G/A
Latest Form
2025-05-15
Most Recent
2014
Filing Since
FinancialsEarningsView All on EDGAR

Source: SEC EDGAR (data.sec.gov) · CIK 0001479290 · Updated hourly · Not investment advice

Latest Annual Report

10-K · Annual ReportFY
Filed Date
2024-02-28
Fiscal Year End
Feb 28, 2024
Accession No.
0001479290-24-000038
Primary Document
rvnc-20231231.htm
View on SEC EDGARDownload PDFFiling Index
Source: data.sec.gov · CIK 0001479290 · Accession 0001479290-24-000038

Latest Key Filings

10-QQuarterly Report
10-Q
2024-11-07
View 10-Q on SEC
8-KCurrent Report
8-K
2025-02-06Material Event
View 8-K on SEC
Form 4Insider Activity
Ownership Change Disclosures

Executive & director trade disclosures. Full buy/sell sentiment analysis on the dedicated tab.

View Insider Trades Tab

SEC Filing History

Hide Form 4 / 144
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-05-15
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-03-06
View
15-12G15-12G
15-12G
2025-02-18
View
SCHEDULE 13G/ASCHEDULE 13G/A
SCHEDULE 13G/A
2025-02-13
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
S-8 POSS-8 POS
S-8 POS
2025-02-12
View
Showing 1–15 of 515 filingsForm 4 / 144 hidden· 947 total in EDGAR

About SEC Filings & 10-K Annual Reports

Data source: SEC EDGAR (data.sec.gov)  |  Updated: Hourly  |  CIK: 0001479290  |  Exchange: NASDAQ · Healthcare

Revance Therapeutics, Inc. (NASDAQ: RVNC) has submitted 947 documents to the U.S. Securities and Exchange Commission (SEC) since its IPO in 2014. As a Healthcare sector company with CIK 0001479290, all filings are publicly accessible via the EDGAR database at no cost.

The annual 10-K report is Revance Therapeutics, Inc.'s most comprehensive regulatory disclosure. The most recent Revance Therapeutics, Inc. 10-K was filed on 2024-02-28 for fiscal year ending 2024. Historical RVNC 10-K annual reports are available from 2009 through 2024.

Investors researching Revance Therapeutics, Inc. SEC filings can access 10-K annual reports, quarterly 10-Q reports, material event 8-K filings, and proxy statements directly from the links above. All documents are sourced from the official SEC EDGAR system.

Source: SEC EDGAR · data.sec.gov · SEC Form 10-K · SEC Form 10-Q · SEC Form 8-K2026-06-10
→ RVNC Financials→ RVNC Earnings→ RVNC Insider Trades

Frequently Asked Questions

RVNC SEC Filings · 8 questions

Revance Therapeutics, Inc. (RVNC) SEC filings are publicly available on this page and on the official SEC EDGAR database at sec.gov. You can browse all 947 filings and access original documents at no cost. Revance Therapeutics, Inc.'s CIK is 0001479290.

RVNC SEC filingsRevance Therapeutics, Inc. SEC documentsfind RVNC 10-K